Co Kildare-based medical and laboratory product supplier, AccuScience last year enjoyed a Covid-19 dividend as pretax profits increased more than 11-fold to €11.6 million.
The Naas medical and laboratory equipment provider, which was taken over earlier this month, was one of the main Irish-based suppliers of equipment to the HSE during the height of the pandemic.
New accounts show revenues at AccuScience Ireland Ltd increased almost four-fold from €16.89 million to €62.95 million in the 18 months to the end of June 2021.
The pretax profit of €11.59 million compared to a profit of €1 million in the previous 12-month period.
Time is money: ‘Every single clock’ sells at auction in Waterford
Aoibhinn Ní Shúilleabháin: ‘I mourned friendships for too long that were actually past their time’
Miriam Lord: Chaos for coalition colleagues as RIGs and Raegionals openly identify as part of opposition
What Michael Lowry’s constituents really think of him
The revenue and pretax profit increase is skewed as the prior period was for 12 months but on a pro-rata basis, revenues last year increased by 152 per cent and pretax profits increased by 610 per cent.
Figures previously released by the HSE show that the market-leading life sciences and med-tech distributor recorded HSE sales in 2020 of €48.4 million for equipment as part of the Covid-19 response.
AccuScience was taken over earlier this month by UK firm Diploma plc for £51 million (€59.9 million).
In a statement, Diploma said AccuScience is expected to contribute annualised revenue of £35 million and the business’s “growth prospects are exciting, underpinned by recent wins and a strong product pipeline”.
Prior to the sale, the ultimate controlling party of AccuScience was Declan Devine.
A breakdown of the firm’s revenues last year show that revenues from the Republic totalled €55.29 million and revenues from the North and Britain totalled €8.65 million.
Numbers employed by the company last year increased by one to 57 as staff costs totalled €4.25 million.
At the end of June 2021, the company had shareholder funds of €23.5 million. The company’s cash funds increased from €279,442 to €1.1 million.
